Violeta Molagic *, Victoria Aramă **, A. Streinu Cercel ***, Otilia Benea ****, Raluca Sandu *****, Athena Negoiţă ******
* Dr. Violeta Molagic – medic specialist boli infecțioase, lnstitutul de Boli lnfecțioase ,,Prof Dr. Matei Balș”, București
** Dr. Victoria Aramă – medic primar boli infecțioase, șef de lucrări UMF Carol Davila, București
*** Prof Dr. Adrian Streinu-Cercel – medic primar boli infecțioase, director al Institutul de Boli lnfecțioase ,,Prof Dr. Matei Balș”, București, profesor universitar UMF Carol Davila
**** Dr. Otilia Benea – medic primar boli infecțioase, șef de lucrări UMF Carol Davila, București
***** Dr. Raluca Sandu – medic rezident boli infecțioase, an IV
****** Dr. Athena Negoiță – medic rezident boli infecțioase, an V
Abstract
Infections with hepatitis viruses B and C (HBV, HCV) major public health issues worldwide, affecting 5% of are population and 3% respectively. Although HBV, HCV are hepatotropic, in the last decades they have been involved in the etiopathogeny of chronic lymphoproliferations (CL). Significantly of studies have shown the presence of DNA HBV in peripheral mononuclears , and its ability to replicate in the lymph nodes and bone marrow. Chronic infection with hepatitis C virus is associated with disturbances of B lymphocyte activation and function. These abnormali ties reflect chronic antigen stimulation or aberrant signal ing through the B-cell coreceptor, the latter mediated by binding of the HCV E2 glycoprotein to CD81. HCV is implicated as possible etiologic factor of type II essential mixed cryoglobulinemia that predisposes to overt B cell malignancy. The malignant non-Hodgkin lymphomas (NHL) are cancers that usually affect B lymphocytes (BL). The prevalence of HBV and HCV infections in patients with CL is significantly higher than in general population.